Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma

By Vaishampayan Ulka   Heilbrun Lance   Shields Anthony   Lawhorn-Crews Jawana   Baranowski Karen   Smith Daryn   Flaherty Lawrence  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 69-75

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

By Vuky Jacqueline   Isacson Christina   Fotoohi Mehran   Cruz Jason   Otero Henry   Picozzi Vincent   Malpass Thomas   Aboulafia David   Jacobs Andrew  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 85-88

Springer Publishing Company

Access to resources Recommend Favorite

A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma

By Peterson Amy   Harlin Helena   Karrison Theodore   Vogelzang Nicholas   Knost James   Kugler John   Lester Eric   Vokes Everett   Gajewski Thomas   Stadler Walter  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 141-149

Springer Publishing Company

Access to resources Recommend Favorite

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3435-3443

Blackwell Publishing

Access to resources Recommend Favorite

Interferon-α plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: A pilot study

By Amato Robert   Rawat Anish  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 171-175

Springer Publishing Company

Access to resources Recommend Favorite